↓
 

Hepatitis C Blog

Hepatitis C Blog
  • Home
  • Eblast SignUp

Tag Archives: cost of treatment

Post navigation

← Older posts

ACLU Files Another Suit Against Indiana Over Hep C Treatment

Hepatitis C Blog Posted on November 28, 2015 by Alan FranciscusDecember 1, 2015

INDIANAPOLIS — The American Civil Liberties Union of Indiana has filed yet another lawsuit against the state, this time against the Family and Social Services Administration. The newest lawsuit is over Medicaid payments for Hepatitis C treatment.

There is a cure for Hepatitis C, but it can cost as much $100,000. Medicaid programs can get the drugs for cheaper, but they’re still expensive. So, to limit the burden on the state, there are requirements. Patients have to have a certain level of liver damage, or they have to also be infected with HIV before Medicaid will pay for the treatment.

Read more…

Share This Page
Facebooktwittergoogle_plusredditpinterestlinkedintumblrmail
Follow Us
Facebooktwitter
Tagged ACLU, cost of treatment, Indiana

One in four hepatitis C patients denied initial approval for drug treatment

Hepatitis C Blog Posted on August 27, 2015 by Alan FranciscusDecember 13, 2015

Nearly one in four patients with chronic hepatitis C (HCV) are denied initial approval for a drug therapy that treats the most common strain of the infection, according to a Yale School of Medicine study.

The finding, published Aug. 27 in PLOS ONE, identifies a new barrier to caring for patients with this severe condition.

Prior to the FDA approval of novel antiviral therapies for HCV in 2014, treatment options for patients were limited, requiring weekly injections of interferon-based therapy that caused severe side effects. The new regimens revolutionized treatment and offered patients an oral therapy with cure rates exceeding 90%. However, the high cost of care led insurers to impose new restrictions on drug authorization. Read more….

Share This Page
Facebooktwittergoogle_plusredditpinterestlinkedintumblrmail
Follow Us
Facebooktwitter
Tagged access to treatment, cost of treatment

One in four hepatitis C patients denied initial approval for drug treatment

Hepatitis C Blog Posted on August 27, 2015 by Alan FranciscusDecember 1, 2015

Nearly one in four patients with chronic hepatitis C (HCV) are denied initial approval for a drug therapy that treats the most common strain of the infection, according to a Yale School of Medicine study.

The finding, published Aug. 27 in PLOS ONE, identifies a new barrier to caring for patients with this severe condition.

Prior to the FDA approval of novel antiviral therapies for HCV in 2014, treatment options for patients were limited, requiring weekly injections of interferon-based therapy that caused severe side effects. The new regimens revolutionized treatment and offered patients an oral therapy with cure rates exceeding 90%. However, the high cost of care led insurers to impose new restrictions on drug authorization.

Read more….

Share This Page
Facebooktwittergoogle_plusredditpinterestlinkedintumblrmail
Follow Us
Facebooktwitter
Tagged access to treatment, cost of treatment

Should We Be Rationing Hepatitis Drugs? Obama Pressured to End Restrictions

Hepatitis C Blog Posted on August 27, 2015 by Alan FranciscusDecember 13, 2015

Amid mounting evidence that federal and state authorities are rationing costly new wonder drugs for treating people with the potentially lethal hepatitis C virus, public health experts have begun pressing the White House to intervene to expand the use of Sovaldi and other new medications.

An estimated 3.2 million adults are chronically infected with hepatitis C while an estimated 20,000 people die from the serious liver ailment every year, including many military veterans.

The New York Times reported on Tuesday that a group of experts from the Public Health Service and President Obama’s Advisory Council on H.I.V./AIDS wrote a letter to the White House complaining that restrictions on the use of these drugs by many states are inconsistent with prudent and sound medical practices. Read more….

Share This Page
Facebooktwittergoogle_plusredditpinterestlinkedintumblrmail
Follow Us
Facebooktwitter
Tagged AbbVie 2D, Abbvie 3D, AbbVie triple DAA, access to treatment, access to treatments, Advocacy, advocacy Fair Pricing Coalition (FPC) Harvoni, cost of treatment, cost-effectveness

Should We Be Rationing Hepatitis Drugs? Obama Pressured to End Restrictions

Hepatitis C Blog Posted on August 27, 2015 by Alan FranciscusDecember 1, 2015

Amid mounting evidence that federal and state authorities are rationing costly new wonder drugs for treating people with the potentially lethal hepatitis C virus, public health experts have begun pressing the White House to intervene to expand the use of Sovaldi and other new medications.

An estimated 3.2 million adults are chronically infected with hepatitis C while an estimated 20,000 people die from the serious liver ailment every year, including many military veterans.

The New York Times reported on Tuesday that a group of experts from the Public Health Service and President Obama’s Advisory Council on H.I.V./AIDS wrote a letter to the White House complaining that restrictions on the use of these drugs by many states are inconsistent with prudent and sound medical practices.

Read more….

Share This Page
Facebooktwittergoogle_plusredditpinterestlinkedintumblrmail
Follow Us
Facebooktwitter
Tagged AbbVie 2D, Abbvie 3D, AbbVie triple DAA, access to treatment, access to treatments, Advocacy, advocacy Fair Pricing Coalition (FPC) Harvoni, cost of treatment, cost-effectveness

New Zealand: Cost keeps cure out of reach for those with Hepatitis C

Hepatitis C Blog Posted on July 27, 2015 by Alan FranciscusDecember 1, 2015

Craig Hopkins, 52, nearly died from liver failure after contracting Hepatitis C virus (HCV) from an amateur tattoo. His new liver developed HCV but was finally cured after treatment with a new unsubsidised drug made available on compassionate grounds.

Now Hepatitis C free, the 52-year-old is calling for Sovaldi
(sofosbuvir) and Harvoni (ledipasvir/sofosbuvir) to be made available in
New Zealand.

“I reckon it’s really sad the drugs are not available. If they were,
it would free up the operating tables and they wouldn’t need to do so
many liver transplants.”

Read more…

Share This Page
Facebooktwittergoogle_plusredditpinterestlinkedintumblrmail
Follow Us
Facebooktwitter
Tagged access to treatment, cost of treatment, New Zealand, Personal Stories

New Zealand: Cost keeps cure out of reach for those with Hepatitis C

Hepatitis C Blog Posted on July 27, 2015 by Alan FranciscusDecember 13, 2015

Craig Hopkins, 52, nearly died from liver failure after contracting Hepatitis C virus (HCV) from an amateur tattoo. His new liver developed HCV but was finally cured after treatment with a new unsubsidised drug made available on compassionate grounds.

Now Hepatitis C free, the 52-year-old is calling for Sovaldi (sofosbuvir) and Harvoni (ledipasvir/sofosbuvir) to be made available in New Zealand.

“I reckon it’s really sad the drugs are not available. If they were, it would free up the operating tables and they wouldn’t need to do so many liver transplants.”

Read more…

Share This Page
Facebooktwittergoogle_plusredditpinterestlinkedintumblrmail
Follow Us
Facebooktwitter
Tagged access to treatment, cost of treatment, New Zealand, Personal Stories

Two Current Fronts of the American Health Care Wars: Hepatitis C and Cancer

Hepatitis C Blog Posted on July 7, 2015 by Alan FranciscusDecember 1, 2015

The Pharmaceutical Industry, Health Insurance and Recurrent Questions of Extortion, Murder and Evil

Asking patients to delay treatment for hepatitis C is like asking patients to delay treatment for diabetes or cancer.

“Waiting for cirrhosis to happen to treat HCV is like waiting
for cancer to metastasize or for diabetes to cause complications before
treating it. In reality, all cause mortality and per patient per year
health care costs are tripled for patients with hepatitis C, whether
they have cirrhosis or not.”

— Dr. Douglas Dieterich, leading hepatitis C and liver diseases researcher and specialist at the Mount Sinai Hospital, New York City

My
friend John is a retired college professor who lives on a budget. He
has hepatitis C, which he acquired from a blood transfusion before the
development of blood testing and screening for hep C. He does have
health insurance, but like most of those seeking treatment for this
condition, he has been told that he must become demonstrably sicker to
qualify for treatment coverage. Meanwhile, he must not drink any alcohol
and remain vigilant for symptoms, especially fatigue. Since the
progression of hepatitis C to cirrhosis of the liver and cancer of the
liver can take decades, and John has already had this disease for
decades, he is understandably concerned. In fact, he may die sooner from
other causes, his untreated hepatitis C playing an indeterminate role.
There is, however, an alternative for John. If he had the $100,000+ in
cash to pay for the treatment now, he could be fully and safely cured in
8-12 weeks. John does not identify himself as a socialist, and he is
willing to pay what he can for treatment, but the cost in this case is
overwhelming.

Read more…

Share This Page
Facebooktwittergoogle_plusredditpinterestlinkedintumblrmail
Follow Us
Facebooktwitter
Tagged activism, cost of treatment, delaying treatment, Disease Progression, ethics, Mortality

Post navigation

← Older posts

Search This Blog

Our Blog Gets Recognized – Three Years in a Row!

The Best Hepatitis C Blogs
The Best Hepatitis C Blogs
The Best Hepatitis C Blogs

Subscribe to our mailing list to receive our posts via email

* indicates required

Share This Site

Facebooktwittergoogle_plusredditpinterestlinkedintumblrmail

Follow HCV Advocate

Facebooktwitter

RSS HCV Advocate Clinical Trials Reference Guide

  • The study is aimed at assessing the safety and immunogenicity of HCV prime-boost vaccinations ChAd3-hliNSmut and MVA-hliNSmut, administered intramuscularly in healthy volunteers and DAA treated patients.
    The study is aimed at assessing the safety and immunogenicity of HCV prime-boost vaccinations ChAd3-hliNSmut and MVA-hliNSmut, administered intramuscularly in healthy volunteers and DAA treated patients. To read the entire study, click here Share This PageFollow Us … Continue reading → The post The study is aimed at assessing the safety and immunogenicity of HCV […]
  • Real-life Security and Efficacy of DAA-based Therapy in 1,000 HCV/HIV-Coinfected Patients – Spain
    The purpose of this study is to evaluate the efficacy and tolerability of DAA-based regimens in the clinical practice in HIV/HCV-coinfected patients. Hypothesis: The efficacy and tolerability of all DAA-based regimens in the clinical practice is different to what is … Continue reading → The post Real-life Security and Efficacy of DAA-based Therapy in 1,000 […]

Archives

  • February 2019 (37)
  • January 2019 (47)
  • December 2018 (34)
  • November 2018 (45)
  • October 2018 (26)
  • September 2018 (28)
  • August 2018 (30)
  • July 2018 (37)
  • June 2018 (28)
  • May 2018 (53)
  • April 2018 (50)
  • March 2018 (55)
  • February 2018 (48)
  • January 2018 (40)
  • December 2017 (28)
  • November 2017 (47)
  • October 2017 (67)
  • September 2017 (63)
  • August 2017 (54)
  • July 2017 (63)
  • June 2017 (57)
  • May 2017 (65)
  • April 2017 (82)
  • March 2017 (55)
  • February 2017 (74)
  • January 2017 (71)
  • December 2016 (76)
  • November 2016 (84)
  • October 2016 (61)
  • September 2016 (66)
  • August 2016 (79)
  • July 2016 (62)
  • June 2016 (56)
  • May 2016 (72)
  • April 2016 (61)
  • March 2016 (55)
  • February 2016 (38)
  • January 2016 (40)
  • December 2015 (48)
  • November 2015 (55)
  • October 2015 (112)
  • September 2015 (105)
  • August 2015 (101)
  • July 2015 (108)
  • June 2015 (97)
  • May 2015 (172)
  • April 2015 (139)
  • March 2015 (218)
  • February 2015 (201)
  • January 2015 (217)
  • December 2014 (93)
  • November 2014 (88)
  • October 2014 (107)
  • September 2014 (84)
  • August 2014 (65)
  • July 2014 (84)
  • June 2014 (71)
  • May 2014 (100)
  • April 2014 (95)
  • March 2014 (89)
  • February 2014 (58)
  • January 2014 (48)
  • December 2013 (60)
  • November 2013 (76)
  • October 2013 (93)
  • September 2013 (77)
  • August 2013 (75)
  • July 2013 (88)
  • June 2013 (77)
  • May 2013 (74)
  • April 2013 (69)
  • March 2013 (66)
  • February 2013 (43)
  • January 2013 (60)
  • December 2012 (40)
  • November 2012 (87)
  • October 2012 (54)
  • September 2012 (61)
  • August 2012 (68)
  • July 2012 (75)
  • June 2012 (58)
  • May 2012 (92)
  • April 2012 (89)
  • March 2012 (60)
  • February 2012 (46)
  • January 2012 (60)
  • December 2011 (54)
  • November 2011 (77)
  • October 2011 (53)
  • September 2011 (49)
  • August 2011 (35)
  • July 2011 (50)
  • June 2011 (33)
  • May 2011 (31)
  • April 2011 (34)
  • March 2011 (33)
  • February 2011 (23)
  • January 2011 (22)
  • December 2010 (18)
  • November 2010 (25)
  • October 2010 (20)
  • September 2010 (7)
  • August 2010 (5)
  • July 2010 (4)
© 2015 HCVAdvocate.org Top of Blog   
↑